"Loading Stock Price & Valuation Data ..."
Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to PROK. [ FAQ on what and how to ask] For non-PROK questions, click the logo in the upper-right corner to return to the main page and ask there.
CEO:Dr. Bruce Culleton M.D.
Headquarter: 2000 Frontis Plaza Boulevard, Suite 250, Winston-Salem, NC, United States, 27103
Industry: Biotechnology, Investment Track: cell therapies, Employees: 231
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
My Watchlist
